Saturday 10 October 2026
Export all BMY data to Excel Powerpack
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
59.12
0.46
−0.77%
Follow BMY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.69 | 17.04 | 15.59 | 15.19 |
+8 more quarters Free account |
P/S ratio |
2.39 | 2.55 | 2.28 | 1.91 | |
P/FCF ratio |
10.29 | 10.38 | 8.54 | 6.00 | |
P/Operating CF |
34.68 | 111.96 | 55.58 | 14.55 | |
P/B ratio |
5.27 | 6.15 | 5.93 | 4.94 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.04 | 3.25 | 2.99 | 2.59 | |
EV/EBITDA |
9.92 | 11.95 | 10.81 | 9.60 | |
EV/Operating CF |
11.71 | 11.84 | 10.18 | 7.48 | |
EV/FCF |
13.09 | 13.23 | 11.22 | 8.12 | |
Quick Ratio |
1.16 | 1.04 | 0.94 | 0.99 | |
Current Ratio |
1.53 | 1.42 | 1.26 | 1.27 | |
Net Debt/EBITDA |
6.85 | 8.86 | 14.06 | 7.87 | |
Debt/Assets |
49.20% | 51.41% | 50.10% | 50.55% | |
Debt/Equity |
1.93 | 2.21 | 2.44 | 2.63 | |
Asset Turnover |
0.54 | 0.54 | 0.53 | 0.50 | |
Operating CF/Net income |
1.02 | 0.41 | 1.82 | 2.87 | |
Capex/Depreciation |
(0.51) | (0.58) | (0.38) | (0.32) | |
Research and Development Expense of Revenue |
22.81% | 23.06% | 20.68% | 20.68% | |
Selling, General and Administrative Expense of Revenue |
14.08% | 14.07% | 17.45% | 14.64% | |
Intangible Assets out of Total Assets |
0.45 | 0.46 | 0.45 | 0.44 | |
Share Based Compensation of Revenue |
1.04% | 1.27% | 1.06% | 1.14% | |
Graham Net Nets |
(0.31) | (0.32) | (0.38) | (0.46) | |
Graham Number |
33.41 | 28.11 | 26.61 | 24.71 | |
Earnings Yield |
7.88% | 5.87% | 6.41% | 6.59% | |
Free Cash Flow Yield |
9.72% | 9.63% | 11.71% | 16.66% | |
Revenue per Share |
6.35 | 5.64 | 6.15 | 6.00 | |
Operating CF per Share |
1.66 | 0.54 | 0.97 | 3.10 | |
Capex per Share |
(0.15) | (0.17) | (0.18) | (0.16) | |
Free Cash Flow per Share |
1.51 | 0.37 | 0.79 | 2.94 | |
Cash per Share |
5.42 | 5.15 | 5.25 | 8.11 | |
Shareholders Equity per Share |
10.93 | 9.86 | 9.10 | 9.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.93 | 9.86 | 9.10 | 9.14 | |
Free Cash Flow |
3,088.00 | 757.00 | 1,604.00 | 5,991.00 | |
Working Capital |
9,920.00 | 8,050.00 | 5,973.00 | 7,494.00 | |
Capital Expenditures |
(305.00) | (347.00) | (370.00) | (320.00) | |
Net Current Asset Value |
(36,736.00) | (39,166.00) | (42,143.00) | (42,659.00) | |
EV/EBIT |
12.57 | 16.42 | 15.45 | 15.48 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
9.88 | 12.88 | 11.76 | 11.43 | |
| Other line items | |||||
Average Receivables |
10,984.00 | 10,084.50 | 11,080.50 | 11,224.00 | |
Average Payables |
4,792.50 | 4,118.00 | 3,588.50 | 3,878.50 | |
Average Inventory |
2,737.00 | 2,711.00 | 2,623.50 | 3,045.00 | |
Average Assets |
91,155.00 | 89,451.50 | 91,320.50 | 95,279.50 | |
Average Common Equity |
19,904.00 | 18,774.50 | 17,446.50 | 17,899.50 |
Columns are period end dates